Sexual dysfunction is a common consequence of prostate cancer treatment, yet many patients go unsupported due to lack of discussion or delays in intervention.
In this video, Professor Mike Kirby outlines why primary care clinicians should re-evaluate when and how PDE5 inhibitors are introduced. The discussion introduces the concept of prehabilitation to help preserve penile tissue integrity and support long term erectile function. It also explores the growing body of evidence suggesting that PDE5 inhibitors may offer benefits beyond sexual health, including improvements in cardiovascular outcomes, glycaemic control and renal function.
In addition to clinical insights, the video addresses common barriers in practice, including outdates perceptions around costs and prescribing restrictions, and highlights the importance of initiating conversations about sexual wellbeing with patients and their partners. This resource is designed to support primary care professionals in delivering more holistic, timely and effective care for patients living with and beyond prostate cancer.
